Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238155 · ClinicalTrials.gov registry record
Evaluation of the Impact of Reduced Immunosuppression
A clinical trial of Graft Vs Host Disease, sponsored by Methodist Health System.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05238155 is a study of Graft Vs Host Disease that has completed, run by Methodist Health System. The registered enrollment target is 100 participants, below the 135-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05238155, a study of Graft Vs Host Disease, has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Graft-versus-host disease (GVHD) is a life-threatening complication of transplantation. It occurs when the donor graft contains immunologically competent T-cells that recognize the recipient as foreign.
Conditions Studied
Interventions
- DRUG antimetabolite
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2025-07-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05238155
The ClinicalTrials.gov registry entry for NCT05238155 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (26% lower). The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 1 intervention - of which antimetabolite is the first listed.
NCT05238155 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05238155 about?
NCT05238155 is a clinical study titled "Evaluation of the Impact of Reduced Immunosuppression". Graft-versus-host disease (GVHD) is a life-threatening complication of transplantation. It occurs when the donor graft contains immunologically competent T-cells that recognize the recipient as foreign.
What is the current status of trial NCT05238155?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2021-10-19. Estimated completion is 2025-07-29.
What conditions does trial NCT05238155 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
What interventions are being tested in trial NCT05238155?
The interventions under investigation include: antimetabolite (DRUG).
Who is sponsoring clinical trial NCT05238155?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05238155 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
RECRUITING
-
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
RECRUITING · NA
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.